Ligand activation of peroxisome proliferator - Activated receptor β/ δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression

Toxicological Sciences

Volumn 105, Issue 2, 2008, Pages 418-428

  Shan, Weiwei ^a,b   Palkar, Prajakta S ^a   Murray, Iain A ^a   Mcdevitt, Emily I ^c   Kennett, Mary J ^a   Kang, Boo Hyon ^d   Isom, Harriet C ^c   Perdew, Gary H ^a   Gonzalez, Frank J ^e   Peters, Jeffrey M ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Non Clinical Pathology Research Center   (South Korea)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hepatotoxicity; Inflammation; Peroxisome proliferator activated receptors

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CALCYCLIN; CARBON TETRACHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIGAND; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; GENOTYPE; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STELLATE CELL; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; INFLAMMATION MEDIATORS; LIGANDS; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR DELTA; PPAR-BETA; PROTECTIVE AGENTS; THIAZOLIDINES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 51849123779     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn142     Document Type: Article

References (97)

1. Ali, F. Y., Egan, K., Fitzgerald, G. A., Desvergne, B., Wahli, W., Bishop-Bailey, D., Warner, T. D., and Mitchell, J. A. (2005). Role of prostacyclin receptor versus PPAR[beta] with treprostinil sodium on lung fibroblast proliferation. Am. J. Respir. Cell. Mol. Biol. 34 242-246.
2. Arsenijevic, D., de Bilbao, F., Plamondon, J., Paradis, E., Vallet, P., Richard, D., Langhans, W., and Giannakopoulos, P. (2006). Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J. Cereb. Blood Flow Metab. 26, 433-445.
3. Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Rion, J. P., Staels, B., Auwerx, J., Laville, M., and Vidal, H. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 48, 1319-1327.
4. Aung, C. S., Faddy, H. M., Uster, E. J., Monteith, G. R., and Roberts-Thomson, S. J. (2006). Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation. Biochem. Biophys. Res. Commun. 340, 656-660.
5. Barish, G. D., Atkins, A. R., Downes, M., Olson, P., Chong, L. W., Nelson, M., Zou, Y., Hwang, H., Kang, H., Curtiss, L., et al. (2008). PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis, Proc. Natl. Acad. Sci. U.S. A. 105 4271-4276.
6. Bassaganya-Riera, J., Reynolds, K., Martino-Catt, S., Cui, Y., Hennighausen, L., Gonzalez, F., Rohrer, J., Benninghoff, A. U., and Hontecillas, R. (2004). Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127, 777-791.
7. Berger, J., and Moller, D. E. (2002). The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
8. Bethea, J. R., Gillespie, G. Y., and Benveniste, E. N. (1992). Interleukin-1 beta induction of TNF-alpha gene expression: Involvement of protein kinase C. J. Cell. Physiol. 152, 264-273.
9. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
10. Brown, S. A., Richards, C. M., Hanscom, H. N., Feng, S. L., and Winkles, J. A. (2003). The Fnl4 cytoplasmic tail binds tamour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J. 371, 395-403.
11. Burdick, A. D., Bility, M. T., Girroir, E. E., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2007). Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19, 1163-1171.
12. Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J. C., Tedgui, A., Haegeman, G., and Staels, B. (1999). Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274, 32048-32054.
13. Di Loreto, S., D'Angelo, B., D'Amico, M. A., Benedetti, E., Cristiano, L., Cinque, B., Cifone, M. G., Ceru, M. P., Festuccia, C., and Cimini, A. (2007). PPARbeta agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y. J. Cell. Physiol. 211 837-847.
14. Ding, G., Cheng, L., Qin, Q., Frontin, S., and Yang, Q. (2006). PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell. Cardiol. 40 821-828.
15. Dogra, C., Changotra, H., Mohan, S., and Kumar, A. (2006). Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem. 281, 10327-10336.
16. Dyroy, E., Rost, T, H., Pettersen, R. J., Halvorsen, B., Gudbrandsen, O. A., Ueland, T., Muna, Z., Muller, F., Nordrehaug, J. E., Aukrust, P., et al. (2007). Tetradecylselenoacetic acid, a PPAR ligand with antioxidant, antiinflammatory, and hypolipidemic properties. Arterioscler. Thromb. Vasc. Biol. 27, 628-634.
17. Enomoto, N., Takei, Y., Hirose, M., Konno, A., Shibuya, T., Matsuyama, S., Suzuki, S., Kitamura, K. I., and Sato, N. (2003). Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther. 306, 846-854.
18. Escher, P., Braissant, O., Basu-Modak, S., Michalik, L., Wahli, W., and Desvergne, B. (2001). Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142, 4195-4202.
19. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruchart, J. C., Deeb, S., et al. (1997). The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272, 18779-18789.
20. Fan, Y., Wang, Y., Tang, Z., Zhang, H., Qin, X., Zhu, Y., Guan, Y., Wang, X., Staels, B., Chien, S., et al. (2008). Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 315-321.
21. Forman, B. M., Chen, J., and Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A. 94, 4312-4317.
22. Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669.
23. Fukumoto, K., Yano, Y., Virgona, N., Hagiwara, H., Sato, H., Senba, H., Suzuki, K., Asano, R., Yamada, K., and Yano, T. (2005). Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett. 579, 3829-3836.
24. Girroir, E. E., Hollingshead, H. E., Billin, A. N., Willson, T. M., Robertson, G. P., Sharma, A. K., Amin, S., Gonzalez, F. J., and Peters, J. M. (2008a). Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 243, 236-243.
25. Girroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., and Peters, J. M. (2008b). Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem. Biophys. Res. Commun. 371, 456-461.
26. Graham, T. L., Mookherjee, C., Suckling, K. E., Palmer, C. N., and Patel, L. (2005). The PPAR[delta] agonist GW0742X reduces atherosclerosis in LDLR-/- mice. Atherosclerosis 181, 29-37.
27. Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., and DuBois, R. N. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 97, 13275-13280.
28. Harman, F. S., Nicol, C. J., Marin, H. E., Ward, J. M., Gonzalez, F. J., and Peters, J. M. (2004). Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med. 10 481-483.
29. Hellemans, K., Michalik L., Dittie, A., Knorr, A., Rombouts, K., De Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., et al. (2003). Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124, 184-201.
30. Hollingshead, H. E., Borland, M. G., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2008). Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29, 169-176.
31. Hollingshead, H. E., Killins, R. L., Borland, M. G., Girroir, E. E., Billin, A. N., Willson, T. M., Sharma, A. K., Amin, S., Gonzalez, F. J., and Peters, J. M. (2007a). Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28, 2641-2649.
32. Hollingshead, H. E., Morimura, K., Adachi, M., Kennett, M. J., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2007b). PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. 52, 2912-2919.
33. Jakobsen, M. A., Petersen, R. K., Kristiansen, K., Lange, M., and Lillevang, S. T. (2006). Peroxisome proliferator-activated receptor alpha, delta, gammal and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands. Scand. J. Immunol. 63 330-337.
34. Joo, J. H., Kim, J. W., Lee, Y., Yoon, S. Y., Kim, J. H., Paik, S. G., and Choe, I. S. (2003). Involvement of NF-kappaB in the regulation of S100A6 gene expression in human hepatoblastorna cell line HepG2. Biochem. Biophys. Res. Commun. 307, 274-280.
35. Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., and Lee, C. H. (2008). Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485-495.
36. Kilgore, K. S., and Billin, A. N. (2008). PPARbeta/delta ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs. 9. 463-469.
37. Kim, D. J., Akiyama, T. E., Harman, F. S., Burns, A. M., Shan, W., Ward, J. M., Kennett, M. J., Gonzalez, F. J., and Peters, J. M. (2004a). Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279, 23719-23727.
38. Kim, D. J., Bility, M. T., Billin, A. N., Willson, T. M., Gonzalez, F. J., and Peters, J. M. (2006). PPARb/d selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13, 53-60.
39. Kim, D. J., Murray, I. A., Burns, A. M., Gonzalez, F. J., Perdew, G. H., and Peters, J. M. (2005). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280, 9519-9527.
40. Kim, H. J., Ham, S. A., Kim, S. U., Hwang, J. Y., Kim, J. H., Chang, K. C., Yabe-Nishimura, C., Kim, J. H., and Seo, H. G. (2008). Transforming growth factor-betal is a molecular target for the peroxisome proliferator-activated receptor delta. Circ. Res. 102, 193-200.
41. Kim, S. H., Kang, Y. J., Kim, W. J., Woo, D. K., Lee, Y., Kim, D. I., Park, Y. B., Kwon, B. S., Park, J. E., and Lee, W. H. (2004b). TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ. J. 68, 396-399.
42. Kino, T., Rice, K. C., and Chrousos, G. P. (2007). The PPARdelta agonist GW501516 suppresses interieukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest. 37, 425-433.
43. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A. 94, 4318-4323.
44. Lee, C. H., Olson, P., Hevener, A., Mehl, I., Chong, L. W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006). PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 103, 3444-3449.
45. Leibowitz, M. D., Fievet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Bergera, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000). Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473, 333-336.
46. Li, D., and Friedman, S. L. (1999). Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J. Gastroenterol. Hepatol. 14, 618-633.
47. Lim, H. J., Lee, S., Park, J. H., Lee, K. S., Choi, H. E., Chung, K. S., Lee, H. H., and Park, H. Y. (2008). PPARdelta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis. doi:10.1016/ j.atherosclerosis.2008.05.023.
48. Liu, C., Gaca, M. D., Swenson, E. S., Vellucci, V. F., Reiss, M., and Wells, R. G. (2003). Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J. Biol. Chem. 278, 11721-11728.
49. Man, M. Q., Barish, G. D., Schmuth, M., Crumrine, D., Barak, Y., Chang, S., Jiang, Y., Evans, R. M., Elias, P. M., and Feingold, K. R. (2007). Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J. Invest. Dermatol. 128, 370-377.
50. Marin, H. E., Peraza, M. A., Billin, A. N., Willson, T. M., Ward, J. M., Kennett, M. J., Gonzalez, F. J., and Peters, J. M. (2006). Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res. 66, 4394-4401.
51. Martinasso, G., Maggiora, M., Trombetta, A., Canuto, R. A., and Muzio, G. (2006). Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544. J. Toxicol. Environ. Health A 69, 353-365.
52. Matsuura, H., Adachi, H., Smart, R. C., Xu, X., Arata, J., and Jetten, A. M. (1999). Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol. Cell. Endocrinol. 147, 85-92.
53. Matthiessen, M. W., Pedersen, G., Albrektsen, T., Adamsen, S., Fleckner, J., and Brynskov, J. (2005). Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand. J. Gastroenterol. 40, 198-205.
54. Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., et al. (2001). Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell. Biol. 154, 799-814.
55. Müller-Brüsselbach, S., Kömhoff, M., Rieck, M., Meissner, W., Kaddatz, K., Adamkiewicz, J., Keil, B., Klose, K. J., Moll, R., Burdick, A. D., et al. (2007). Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J. 26 3686-3698.
56. Nadra, K., Anghel, S. I., Joye, E., Tan, N. S., Basu-Modak, S., Trono, D., Wahli, W., and Desvergne, B. (2006). Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol. Cell. Biol. 26 3266-3281.
57. Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., and Shibata, N. (2006). Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536, 182-191.
58. Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., and Chawla, A. (2008). Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496-507.
59. Oliver, W. R., Jr., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001). A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci U.S.A. 98, 5306-5311.
60. Otsuyama, K. I., Ma, Z., Abroun, S., Amin, J., Shamsasenjan, K., Asaoku, H., and Kawano, M. M. (2007). PPARbeta-mediated growth suppression of baicalein and dexamethasone in human myeloma cells. Leukemia 21 187-190.
61. Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., and Peters, J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269-295.
62. Peters, J. M., Lee, S. S. T., Li, W., Ward, J. M., Gavrilova, O., Everett, C., Reitman, M. L., Hudson, L. D., and Gonzalez, F. J. (2000). Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20, 5119-5128.
63. Planaguma, A., Claria, J., Miquel, R., Lopez-Parra, M., Titos, E., Masferrer, J. L., Arroyo, V., and Rodes, J. (2005). The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 19, 1120-1122.
64. Planavila, A., Rodriguez-Calvo, R., Jove, M., Michalik, L., Wahli, W., Laguna, J. C., and Vazquez-Carrera, M. (2005). Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65 832-841.
65. Polak, P. E., Kalinin, S., Dello Russo, C., Gavrilyuk, V., Sharp, A., Peters, J. M., Richardson, J., Willson, T. M., Weinberg, G., and Feinstein, D. L. (2005). Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168, 65-75.
66. Polavarapu, R., Gongora, M. C., Winkles, J. A., and Yepes, M. (2005). Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathwhy activation. J. Neurosci. 25, 10094-10100.
67. Ravaux, L., Denoyelle, C., Monne, C., Limon, I., Raymondjean, M., and El Hadri, K. (2007). Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: Cooperation between PPARbeta and the proto-oncogene BCL-6. Mol. Cell. Biol. 27, 8374-8387.
68. Reed, K. R., Sansom, O. J., Hayes, A. J., Gescher, A. J., Winton, D. J., Peters, J. M., and Clarke, A. R. (2004). PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23 8992-8996.
69. Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008). Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic, abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57, 332-339.
70. Rival, Y., Beneteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J. F., Junquero, D., Colpaert, F. C., and Delhon, A. (2002). PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435, 143-151.
71. Roberts, R. A., Ganey, P. E., Ju, C., Kamendulis, L. M., Rusyn, I., and Klaunig, J. E. (2007). Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci. 96, 2-15.
72. Rodriguez-Calvo, R., Serrano, L., Coll, T., Moullan, N., Sanchez, R. M., Merlos, M., Palomer, X., Laguna, J. C., Michalik, L., Wahli, W., et al. (2008). Activation of peroxisome proliferator-activated receptor {beta}/{delta} (PPAR {beta}/{delta}) inhibits LPS-induced cytokine production in adipocytes by lowering NF-{kappa}B activity via ERK1/2. Diabetes. doi 10.2337/db08-0176.
73. Saluja, I., Granneman, J. G., and Skoff, R. P. (2001). PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33, 191-204.
74. Schmuth, M., Haqq, C. M., Cairns, W. J., Holder, J. C., Dorsam, S., Chang, S., Lau, P., Fowler, A. J., Chuang, G., Moser, A. H., et al. (2004). Peroxisome proliferator-activated receptor (PPAR -beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. 122, 971-983.
75. Sertznig, P., Seifert, M., Tilgen, W., and Reichrath, J. (2008). Cross-regulation of peroxisome proliferator-activated receptor- (PPAR) and vitamin D receptor-signaling pathways in melanoma cells. Exp. Dermatol. 17, 626-627.
76. Shan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., and Peters, J. M. (2008). Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 41, 225-235.
77. Shearer, B. G., and Hoekstra, W. J. (2003). Recent advances in peroxisome proliferator-activated receptor science. Curr. Med. Chem. 10, 267-280.
78. Sheng, L., Ye, P., Liu, Y. X., Han, C. G., and Zhang, Z. Y. (2008). Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin. Exp. Hypertens. 30, 109-119.
79. Stoehr, S. A., and Isom, H. C. (2003). Gap junction-mediated intercellular communicatiou in a long-term primary mouse hepatocyte culture system. Hepatology 38, 1125-1135.
80. Takata, Y., Liu, J., Yin, F., Collins, A. R., Lyon, C. J., Lee, C. H., Atkins, A. R., Downes, M., Barish, G. D., Evans, R. M., et al. (2008). PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 105, 4277-4282.
81. Tan, N. S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Fluhmann, B., Desvergne, B., and Wahli, W. (2001). Critical roles of PPARbeta/delta in keratinocyte response to inflammation. Genes Dev. 15, 3263-3277.
82. Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003). Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100, 15924-15929.
83. Teunissen, B. E., Smeets, P. J., Willemsen, P. H., De Windt, L. J., Van der Vusse, G. J., and Van Bilsen, M. (2007). Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc. Res. 75, 519-529.
84. Uchimura, K., Nakamuta, M., Enjoji, M., Irie, T., Sugimoto, R., Muta, T., Iwamoto, H., and Nawata, H. (2001). Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33, 91-99.
85. Varnat, F., Heggeler, B. B., Grisel, P., Boucard, N., Corthesy-Theulaz, I., Wahli, W., and Desvergne, B. (2006). PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 131, 538-553.
86. Vosper, H., Khoudoli, G. A., and Palmer, C. N. (2003). The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester. Nucl. Recept. 1, 9.
87. Wang, D., Wang, H., Guo, Y., Ning, W., Katkuri, S., Wahli, W., Desvergne, B., Dey, S. K., and Dubois, R. N. (2006). Crosstalk between peroxisome proliferator-activated receptor {delta} and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U.S.A. 103, 19069-19074.
88. Wang, D., Wang, H., Shi, Q., Katkuri, S., Walhi, W., Desvergne, B., Das, S. K., Dey, S. K., and DuBois, R. N. (2004). Prostaglandin E(2) promotes colorectal adenoma growth via trarisactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6, 285-295.
89. Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. I., and Glass, C. K. (2003). PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U.S.A. 100, 6712-6717.
90. Werling, U., Siehler, S., Litfin, M., Nau, H., and Gottlicher, M. (2001). Induction, of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol. Pharmacol. 59, 1269-1276.
91. Westergaard, M., Henningsen, J., Johansen, C., Rasmussen, S., Svendsen, M. L., Jensen, U. B., Schroder, H. D., Staels, B., Iversen, L., Bolund, L., et al. (2003). Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J. Invest. Dermatol. 121, 1104-1117.
92. Westergaard, M., Henningsen, J., Svendsen, M. L., Johansen, C., Jensen, U. B., Schroder, H. D., Kratchmarova, I., Berge, R. K., Iversen, L., Bolund, L., et al. (2001). Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116, 702-712.
93. Willson, T. M., Brown, P. J., Sternbach, D. D., and Henke, B. R. (2000). The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43, 527-550.
94. Woo, C. H., Massett, M. P., Shishido, T., Itoh, S., Ding, B., McClain, C., Che, W., Vulapalli, S. R., Yan, C., and Abe, J. I. (2006). ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. J. Biol. Chem. 281, 32164-32174.
95. Xu, L., Han, C., Lim, K., and Wu, T. (2006a). Cross-tatk between peroxisome proliferator-activated receptor {delta} and cytosolic phospholipase A2 {alpha}/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 66, 11859-11868.
96. Xu, L., Han, C., and Wu, T. (2006b). A novel positive feedback loop between PPARdelta and PGE2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem. 281, 33982-33996.
97. Yang, L., Zhou, Z. G., Zheng, X. L., Wang, L., Yu, Y. Y., Zhou, B., Gu, J., and Li, Y. (2008). RNA interference against peroxisome proliferator-activated receptor delta gene promotes proliferation of human colorectal cancer cells. Dis. Colon Rectum 51, 318-328.